Compare Stocks: VTVT, RLMD, AVIR, and BIOA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$5.27 -7.2%	$5.09	$2.78 ▼ $6.45	$455.56M	0.28	223,148 shs	430,819 shs
BIOA BioAge Labs	$9.17 -2.4%	$15.59	$4.68 ▼ $25.95	$431.20M	0.94	513,552 shs	488,307 shs
RLMD Relmada Therapeutics	$4.09 -3.8%	$5.14	$1.44 ▼ $8.00	$453.35M	0.45	899,192 shs	1.59 million shs
VTVT vTv Therapeutics	$33.29 +1.5%	$32.83	$18.97 ▼ $44.00	$129.16M	0.29	48,633 shs	39,544 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	-7.22%	-7.54%	+4.98%	+20.87%	+66.77%
BIOA BioAge Labs	-2.45%	-5.76%	-19.91%	-44.26%	+84.14%
RLMD Relmada Therapeutics	-3.76%	-9.91%	-9.91%	-37.27%	+162.18%
VTVT vTv Therapeutics	+1.52%	-0.33%	-2.92%	+5.38%	+68.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$5.27 -7.2%	$5.09	$2.78 ▼ $6.45	$455.56M	0.28	223,148 shs	430,819 shs
BIOA BioAge Labs	$9.17 -2.4%	$15.59	$4.68 ▼ $25.95	$431.20M	0.94	513,552 shs	488,307 shs
RLMD Relmada Therapeutics	$4.09 -3.8%	$5.14	$1.44 ▼ $8.00	$453.35M	0.45	899,192 shs	1.59 million shs
VTVT vTv Therapeutics	$33.29 +1.5%	$32.83	$18.97 ▼ $44.00	$129.16M	0.29	48,633 shs	39,544 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	-7.22%	-7.54%	+4.98%	+20.87%	+66.77%
BIOA BioAge Labs	-2.45%	-5.76%	-19.91%	-44.26%	+84.14%
RLMD Relmada Therapeutics	-3.76%	-9.91%	-9.91%	-37.27%	+162.18%
VTVT vTv Therapeutics	+1.52%	-0.33%	-2.92%	+5.38%	+68.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.33	Hold	$7.00	32.83% Upside
BIOA BioAge Labs	2.71	Moderate Buy	$36.57	298.82% Upside
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	193.40% Upside
VTVT vTv Therapeutics	2.78	Moderate Buy	$55.83	67.72% Upside

Current Analyst Ratings Breakdown

Latest VTVT, RLMD, AVIR, and BIOA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	BIOA BioAge Labs	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/8/2026	BIOA BioAge Labs	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/2/2026	VTVT vTv Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/13/2026	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$6.00 ➝ $7.00
8/11/2026	VTVT vTv Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
8/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/6/2026	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$45.00 ➝ $42.00
8/3/2026	BIOA BioAge Labs	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
7/31/2026	BIOA BioAge Labs	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
7/31/2026	BIOA BioAge Labs	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$3.53 per share	N/A
BIOA BioAge Labs	$8.99M	46.82	N/A	N/A	$7.59 per share	1.21
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A
VTVT vTv Therapeutics	$1.02M	128.59	N/A	N/A	$16.36 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$158.35M	-$2.08	N/A	N/A	N/A	N/A	-64.25%	-57.12%	11/11/2026 (Estimated)
BIOA BioAge Labs	-$80.61M	-$2.38	N/A	N/A	N/A	-912.26%	-28.99%	-27.09%	N/A
RLMD Relmada Therapeutics	-$57.38M	-$0.90	N/A	N/A	N/A	N/A	-47.52%	-43.97%	11/12/2026 (Estimated)
VTVT vTv Therapeutics	-$26.97M	-$1.06	N/A	N/A	N/A	N/A	-6.27%	-5.06%	11/5/2026 (Estimated)

Latest VTVT, RLMD, AVIR, and BIOA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	AVIR Atea Pharmaceuticals	-$0.5550	-$0.41	+$0.1450	-$0.41	$33.03 million	N/A
8/6/2026	Q2 2026	RLMD Relmada Therapeutics	-$0.1995	-$0.11	+$0.0895	-$0.11	N/A	N/A
8/6/2026	Q2 2026	VTVT vTv Therapeutics	-$0.97	-$1.05	-$0.08	-$1.05	$0.33 million	N/A
8/5/2026	Q2 2026	BIOA BioAge Labs	-$0.65	-$0.58	+$0.07	-$0.58	N/A	$2.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIOA BioAge Labs	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	8.13	8.13
BIOA BioAge Labs	N/A	17.19	17.19
RLMD Relmada Therapeutics	N/A	29.52	29.52
VTVT vTv Therapeutics	N/A	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
BIOA BioAge Labs	N/A
RLMD Relmada Therapeutics	45.24%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	21.60%
BIOA BioAge Labs	17.55%
RLMD Relmada Therapeutics	14.50%
VTVT vTv Therapeutics	5.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	80.21 million	62.88 million	Optionable
BIOA BioAge Labs	N/A	45.90 million	37.84 million	N/A
RLMD Relmada Therapeutics	10	106.67 million	91.20 million	Optionable
VTVT vTv Therapeutics	9	3.94 million	3.70 million	Not Optionable

VTVT, RLMD, AVIR, and BIOA Headlines

Recent News About These Companies

vTv Therapeutics (NASDAQ:VTVT) Raised to Hold at Zacks Research

September 9 at 7:05 AM | marketbeat.com

Lifesci Capital Upgrades vTv Therapeutics (NASDAQ:VTVT) to Strong-Buy

September 4, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

September 3, 2026 | theglobeandmail.com

vTv Therapeutics to Participate in September Investor Conferences

September 2, 2026 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below 50-Day Moving Average - Should You Sell?

September 2, 2026 | marketbeat.com

vTv Therapeutics Inc. Cl A

August 30, 2026 | barrons.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 19, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts

August 18, 2026 | marketbeat.com

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2026 | markets.businessinsider.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 28, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 2, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next

May 17, 2026 | finance.yahoo.com

Why vTv Therapeutics Inc.’s (VTVT) Stock Is Down 8.13%

May 16, 2026 | aaii.comA

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

May 15, 2026 | zacks.com

vTv Therapeutics Expands At-The-Market Share Program Capacity

May 13, 2026 | tipranks.com

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 8, 2026 | globenewswire.com

vTv Therapeutics to Participate in Upcoming May Investor Conferences

May 7, 2026 | globenewswire.com

Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?

April 20, 2026 | zacks.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT, RLMD, AVIR, and BIOA Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$5.27 -0.41 (-7.22%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$5.22 -0.05 (-0.95%)

As of 09/9/2026 07:30 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

BioAge Labs NASDAQ:BIOA

$9.17 -0.23 (-2.45%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$9.27 +0.10 (+1.10%)

As of 06:39 AM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Relmada Therapeutics NASDAQ:RLMD

$4.09 -0.16 (-3.76%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$4.14 +0.05 (+1.34%)

As of 06:56 AM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

vTv Therapeutics NASDAQ:VTVT

$33.29 +0.50 (+1.52%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$33.48 +0.19 (+0.58%)

As of 05:32 AM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTVT, RLMD, AVIR, and BIOA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTVT, RLMD, AVIR, and BIOA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTVT, RLMD, AVIR, and BIOA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT, RLMD, AVIR, and BIOA Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

BioAge Labs NASDAQ:BIOA

Relmada Therapeutics NASDAQ:RLMD

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTVT, RLMD, AVIR, and BIOA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTVT, RLMD, AVIR, and BIOA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTVT, RLMD, AVIR, and BIOA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT, RLMD, AVIR, and BIOA Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

BioAge Labs NASDAQ:BIOA

Relmada Therapeutics NASDAQ:RLMD

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools